The long-term efficacy and safety data significantly derisk TransCon PTH and support its commercial potential in hypoparathyroidism. Monitor upcoming quarterly reports for revenue growth from Yorvipath (palopegteriparatide) sales, as this data should aid physician adoption.
Price Chart
Executive Summary
Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypoparathyroidism, showing sustained efficacy and safety over 3.5 years. Key results include 86% responders, 100% independence from active vitamin D, 96% independence from therapeutic calcium, normalized kidney function, and no anti-PTH antibodies. The data reinforce the drug's long-term value proposition.
Key Facts
- 86% of patients met the multi-component responder endpoint (normal serum calcium, no active vitamin D, ≤600 mg/day calcium).
- 100% of patients achieved independence from active vitamin D.
- 96% of patients achieved independence from therapeutic doses of calcium (<600 mg/day).
- Mean eGFR increased by 11.0 mL/min/1.73m² from baseline and was maintained through Week 182, contrasting with age-related decline.
- Mean 24-hour urine calcium normalized within 26 weeks and remained normal.
- No patients developed anti-PTH antibodies during 3.5 years of treatment.
- No new safety signals; no discontinuations related to study drug.
Financial Impact
No financial data provided; the filing contains clinical trial results only.
Risk Factors
- Commercial adoption may be slower than expected due to competition or payer dynamics.
- Regulatory updates or label changes could impact market access.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-270227 |
| Document: 0001193125-26-270227-index-headers.html | 0001193125-26-270227 |
| Document: 0001193125-26-270227-index.html | 0001193125-26-270227 |
| Document: 0001193125-26-270227.txt | 0001193125-26-270227 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access